Abstract
Logistic regressions are subject to high uncertainty when the data are not past the inflection point. For example, for logistic regressions estimated with data up to or before inflection point, uncertainties in the upper asymptotic value K can be of the same order of magnitude of the population under analysis. This paper presents a method for uncertainty reduction in logistic regression using data from a surrogate logistic process. We illustrate the procedure using the Richards’ growth function (Generalized Logistic Function) to make predictions for COVID-19 evolution in Brazilian cities at stages before and during their epidemic inflection points. We constrain the logistic function regression with K calculated from selected surrogate international cities where the epidemic is clearly past its inflection point. Information gained with this constraint stabilizes the logistic regression, reducing the uncertainty in the curves’ parameters, including the rate of growth at the inflection point. The uncertainty is reduced even when the actual surrogate K is used just as an anchor to simulate different epidemic scenarios. Results predicted for COVID-19 trajectories within Brazil agree with actual data. These results suggest that in the absence of big data, a simple logistic regression may provide low uncertainty if surrogate cities have been identified for estimates of K, even if the specifics of the evolution in the surrogate cities are different. The method may be used for other logistic models and for other logistic processes in other areas such as economics and biology, if surrogate processes can be identified.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Authors report that the present work received no funding or financial support of any form.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was waived since only public data with non-identifying, collective, information was employed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript is made available in a public repository. See https://github.com/bhvieira/SurrogateLocalitiesCovid
https://github.com/bhvieira/SurrogateLocalitiesCovid
https://www.ibge.gov.br/cidades-e-estados/
https://bigdata-api.fiocruz.br/relatorios/
https://www.census.gov/data/tables/time-series/demo/popest/2010s-total-cities-and-towns.html
https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series
http://demo.istat.it/bilmens2019gen/index.html
https://statistichecoronavirus.it/regioni-coronavirus-italia/lombardia/
http://www.madrid.org/iestadis/fijas/estructu/demograficas/padron/estructupopc.htm
https://www.comunidad.madrid/servicios/salud/2019-nuevo-coronavirus